


Figure S5



Overall survival (OS) (A, C, E) and progression-free survival (PFS) (B, D, F) of patients enrolled in BIOMARK and AVAglio (placebo group) studies stratified by Phillips et al.¹ subtypes:

mesenchymal (A, B), proliferative (C, D), and proneural (E, F). Median values with 95% confidence intervals (CIs) and 2-year survival rates are indicated for each subtype.

1. Phillips, Cancer Cell. 2006;9(3):157-73)